All Updates

All Updates

icon
Filter
Partnerships
NCC Japan partners with PREMIA and Paradigm to establish nationwide cancer clinical trial network
Clinical Trial Technology
Nov 5, 2024
This week:
Partnerships
Apple discloses use of AWS GenAI chips at re:Invent 2024 conference
Generative AI Infrastructure
Today
Product updates
AWS launches Automated Reasoning checks to combat AI hallucinations
Generative AI Infrastructure
Today
Product updates
Roonyx releases enhanced BNPL platform to facilitate secure transactions
Buy Now, Pay Later
Yesterday
Product updates
AWS announces next generation of SageMaker platform at re:Invent 2024
Generative AI Infrastructure
Yesterday
Product updates
Equal1 launches quantum controller chip for cryogenic computing
Quantum Computing
Yesterday
Partnerships
Exotec partners with BlueStar to deploy Skypod warehouse automation system
Logistics Tech
Yesterday
Partnerships
Amaero enters long-term supply agreement with Perryman
Additive Manufacturing
Yesterday
Product updates
Raise3D launches six new resins for DF2 DLP solution
Additive Manufacturing
Yesterday
M&A
Anzu Partners acquires voxeljet for EUR 20 million
Additive Manufacturing
Yesterday
Funding
Soda Health raises USD 50 million in oversubscribed Series B funding to scale operations
Health Benefits Platforms
Yesterday
Clinical Trial Technology

Clinical Trial Technology

Nov 5, 2024

NCC Japan partners with PREMIA and Paradigm to establish nationwide cancer clinical trial network

Partnerships

  • The National Cancer Center (NCC) Japan, Precision Medicine Asia (PREMIA), and Paradigm Health have partnered to launch LC-SCRUM-CD, a nationwide clinical trial network for cancer research in Japan.

  • The collaboration will leverage LC-SCRUM-Asia's network of 150+ hospitals for cancer genomic screening. PREMIA will manage the data platform, and Paradigm will provide its end-to-end clinical trial platform. The partnership aims to increase global pharmaceutical-sponsored trials in Japan while reducing the operational burden on healthcare providers.

  • The initiative builds upon NCC Hospital East's clinical trial capabilities, which currently run over 500 studies annually. It will enable more efficient patient selection for clinical trials through the integration of genetic analysis results and clinical data.

  • Analyst QuickTake: This is the second partnership Paradigm has established in Japan. Earlier this year, Paradigm partnered with Fujitsu , a global technology company, to improve clinical trials and address drug loss in Japan. The company appears to be continuing its global expansion strategy, focusing on Japan.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.